Clinical trials: Pertuzumab
Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma
This is a prospective, single-center, randomized controlled phase II clinical trial.It plans to enroll a total of 24 eligible patients with locally advanced gastric/gastroesophageal junction adenocarcinoma who are HER2-positive…
- Trial name
- NCT07716111
- Testing
- Trastuzumab Rezatecan and Retlirafusp alfa, Trastuzumab Rezatecan and Retlirafusp alfa+Pertuzumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Breast Cancer
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
This study is to explore the efficacy and safety of the first-line treatment of HER2 positive recurrent/metastatic breast cancer with Inetetamab combined with Pertuzumab or Pyrotinib combined with chemotherapy, hoping to have…
- Trial name
- IFANS (NCT06641544)
- Testing
- Inetetamab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
This study evaluates HER2-PET/CT-guided dynamic optimization of neoadjuvant therapy in patients with early-stage HER2-positive breast cancer.
- Trial name
- NCT07527806
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab
- Volunteers
- 156 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of participants with human epidermal growth factor…
- Trial name
- NCT02445586
- Testing
- Docetaxel, Pertuzumab, Trastuzumab
- Where
- 9 sites in India
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
A single-arm, multicenter, real-world observational study of pyrotinib combined with trastuzumab for maintenance therapy after first-line TH (P) therapy for HER2+ABC
- Trial name
- NCT06754059
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- zhangjie
Breast Cancer
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no…
- Trial name
- NCT03264547
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 446 people
- Sponsor
- Japan Breast Cancer Research Group
HER-2 Positive Breast Cancer, Breast Cancer
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2.
- Conditions
- HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT02326974
- Testing
- T-DM1, Pertuzumab, Excision of tumor/mastectomy
- Where
- 4 sites in United States
- Volunteers
- 164 people
- Sponsor
- Dana-Farber Cancer Institute
HER-2 Positive Breast Cancer
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)
Although neoadjuvant dual anti-HER2-targeted therapy, pertuzumab and trastuzumab, combined with taxanes increased the pCR rate for patients with early-stage HER2-positive breast cancer when compared with single blockade combined…
- Trial name
- UC HER (NCT07565324)
- Testing
- Lipo-Dox®, Cyclophosphamide, Trastuzumab (Herceptin)
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- National Taiwan University Hospital
Early Breast Cancer
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta.
- Trial name
- NCT02738970
- Testing
- Trastuzumab, Pertuzumab
- Where
- 2 sites in New Zealand
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
- Trial name
- NCT05572645
- Testing
- Pyrotinib Plus Trastuzumab, Pertuzumab Plus Trastuzumab
- Where
- China
- Volunteers
- 333 people
- Sponsor
- Fudan University
Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model
This study is a phase III clinical trial to explore the efficacy and safety of HER2-positive breast cancer neoadjuvant adaptive therapy compared with standard therapy based on multi-omics data, and to explore a new prediction…
- Trial name
- NCT07239271
- Testing
- The control group, Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response
- Volunteers
- 2,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Healthy Men
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
PERT-1/12102020 is a double-blind randomized single-center clinical trial comparing pharmacokinetics, immunogenicity and safety profiles of Pertuzumab (manufactured by Mabscale, LLC) compared to Perjeta® in healthy men.
- Trial name
- NCT05825781
- Testing
- Pertuzumab, Perjeta®
- Where
- Russia
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Mabscale, LLC
Breast Cancer
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Neoadjuvant therapy is given to breast cancer patients whose cancers are relatively large or have spread to lymph nodes or both.
- Trial name
- NCT02789657
- Testing
- paclitaxel, Trastuzumab, Pertuzumab
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Brown University
Breast Cancer
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
This study is a prospective, multi-center, single-arm, two-cohort, exploratory study, aiming to explore the effectiveness and safety of neoadjuvant treatment with weekly utidelone combined with cisplatin in breast cancer patients.
- Trial name
- NeoURANIA (NCT06510465)
- Testing
- utidelone, Cisplatin, Trastuzumab
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- RenJi Hospital
Breast Cancer
Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab
In China, pyrotinib is used for patients with HER2-positive advanced breast cancer who have progressed on trastuzumab. As anti-HER2 antibody therapy has advanced from trastuzumab monotherapy to trastuzumab-pertuzumab dual-target…
- Trial name
- NCT07810634
- Testing
- Pyrotinib 400mg
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
HER2-positive Breast Cancer
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis.
- Trial name
- TaxCbHER2 (NCT06722612)
- Where
- China
- Volunteers
- 2,916 people
- Sponsor
- Shu Wang
Breast Neoplasm Female
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
This study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.
- Trial name
- NCT05969184
- Testing
- CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
- Where
- 2 sites in China
- Volunteers
- 94 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer Female
CARdiac Function Evaluation in Breast Cancer Patients
This study will investigate the influence of systemic adjuvant/neoadjuvant therapy (SAT: chemotherapy +/- anti-HER2 antibodies (trastuzumab +/- pertuzumab) on heart function/rhythm and cardio-respiratory fitness in recently…
- Trial name
- CARE-B (NCT03266809)
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Swansea University
Metastatic Breast Cancer, HER2-positive Breast Cancer
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
Heroes is a multicentre, national, non-randomized, open-label, phase 2 study. The goal of this clinical trial is to evaluate the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer with disease…
- Trial name
- HEROES (NCT06450314)
- Testing
- Discontinuation of the anti-HER2 maintenance therapy, Monitoring with signatera test
- Where
- France
- Volunteers
- 170 people
- Sponsor
- UNICANCER
Breast Neoplasms
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line…
- Trial name
- PERUSE (NCT01572038)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 299 sites in Algeria, Argentina and 37 more
- Volunteers
- 1,436 people
- Sponsor
- Hoffmann-La Roche